Frequent upregulation of MYC in plasma cell leukemia

Genes Chromosomes and Cancer

Volumn 48, Issue 7, 2009, Pages 624-636

  Chiecchio, Laura ^a   Dagrada, Gian Paolo ^a   White, Helen E ^a   Towsend, Mark R ^a   Protheroe, Rebecca K M ^a   Kan, Luk Cheung ^a   Stockley, David M ^a   Orchard, Kim H ^b,c   Cross, Nicholas C P ^a   Harrison, Christine J ^d   Ross, Fiona M ^a  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 13; CHROMOSOME 16; CHROMOSOME 8; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; GENE NUMBER; GENE TARGETING; GENE TRANSLOCATION; GENOME ANALYSIS; HUMAN; MALE; METAPHASE; METASTASIS; ONCOGENE MYC; PLASMA CELL LEUKEMIA; PLOIDY; PRIMARY TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; AGED, 80 AND OVER; BONE MARROW; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MYC; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; YOUNG ADULT;

EID: 67449096019     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20670     Document Type: Article

References (48)

1. Avet-Loiseau H, Andree-Ashley LE, Moore D, Mellerin MP, Feusner J, Bataille R, Pallavicini MG. 1997. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 19:124-133. (Pubitemid 27231487)
2. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M, Desangles F, Ramond S, Talmant P, Bataille R. 2001a. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: A study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Graupe Francais de Cytogenetique Hematologique. Blood 97:822-825. (Pubitemid 32113422)
3. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R. 2001b. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98:3082-3086.
4. Azar GM, DiPillo F, Gogineni SK, Codec CJ, Verma RS. 1997. Highly complex chromosomal aberrations in bone marrow of a patient with metastatic prostate neoplasm. Cancer Genet Cytogenet 99:116-120. (Pubitemid 27514981)
5. Birnie GD. 1988. The HL60 cell line: A model system for studying human myeloid cell differentiation. Br J Cancer Suppl 9:41-45. (Pubitemid 19054738)
6. Branford S, Hughes TP, Rudzki Z. 1999. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107:587-599.
7. Bryant B, Danaee H, Lichter D, Shaughnessy J, Bergsagel L, Sonneveld P, Anderson K, Boral A, Trepicchio WL, Mulligan G. 2008. High-resolution assessment of chromosomal gains and losses in multiple myeloma tumours from bortezomib clinical trial. J Clin Oncol 26:8570.
8. Chang H, Sloan S, Li D, Patterson B. 2005. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet 156:150-153. (Pubitemid 40092353)
9. Chang H, Qi X, Yeung J, Rcece D, Xu W, Patterson B. 2008. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 33:259-262.
10. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, Cabanas ED, Parker T, Nightingale M, Wechalekar A, Orchard KH, Harrison CJ, Cross NC, Morgan GJ, Ross FM. 2006. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20:1610-1617.
11. Cross NC, Lin F, Goldman JM. 1994. Appropriate controls for reverse transcription polymerase chain reaction (RT-PCR). Br J Haematol 87:218. (Pubitemid 24207028)
12. Dewald GW, Kyle RA, Hicks GA, Greipp PR. 1985. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380-390. (Pubitemid 15007030)
13. Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, Barlogie B, Shaughnessy J, Jr., Kuehl WM. 2006. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: Bi-allelic deletion vs increased expression. Cell Div 1:23. (Pubitemid 46731034)
14. Dib A, Gabrea A, Glebov O, Bergsagel L, Kuehl M. 2008. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 39:25-31.
15. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. 1994. Primary plasma cell leukaemia. Br J Haematol 88:754-759. (Pubitemid 24375790)
16. Eymin B, Gazzeri S, Brambilla C, Brambilla E. 2002. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumours. Oncogene 21:2750-2761. (Pubitemid 34478333)
17. Facon T, Lai JL, Nataf E, Preudhomme C, Zandecki M, Hammad M, Wattel E, Jouet JP, Bauters F. 1993. Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: A report on 46 patients. Br J Haematol 84:743-745.
18. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De MD, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ. 2003. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe against cancer program. Leukemia 17:2318-2357.
19. Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD, Jr., Sawyer JR, Kuehl WM. 2008. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer 47:573-590.
20. Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Mora MJ, Fernandez-Calvo J, Sanz MA, Perez-Simon JA, Rasillo A, Miguel JF. 1999. Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 93:1032-1037. (Pubitemid 29067869)
21. Gutierrez NC, Hernandez JM, Garcia JL, Canizo MC, Gonzalez M, Hernandez J, Gonzalez MB, Garcia-Marcos MA, San Miguel JF. 2001. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 15:840-845. (Pubitemid 32492709)
22. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. 1998. Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512.
23. International Myeloma Working Group. 2003. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 121:749-757. (Pubitemid 36718191)
24. Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs CE, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ. 2007. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110:3291-3300.
25. Jin Y, Mertens F, Kullendorff CM, Panagopoulos I. 2006. Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma. Neoplasia 8:413-418. (Pubitemid 43830748)
26. Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CE. 2006. Primary plasma cell leukemia: Morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol 10:263-268. (Pubitemid 44345269)
27. Knutsen T, Vakulchuk A, Mosijczuk AD, Gabrea A, Ried T, Tretyak N. Complex rearrangements involving der(8)t(8;20) and der(14)t(8;14)t(11;14), CCND1, and duplication of IgH constant region in acute plasmablastic leukemia. 2006. Cancer Genet Cytogenet 164:137-141.
28. Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, Shedden K, Malek SN. 2008. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood 112:1993-2003.
29. Kunz F, Shalaby T, Lang D, von BA, Hainfellner JA, Slave I, Tabatabai G, Grotzer MA. 2006. Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. Neuropathology 26:393-399. (Pubitemid 44454408)
30. Kyle RA, Maldonado JE, Bayrd ED. 1974. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 133:813-818.
31. Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Sun J, Isascs JT, Chang BL, Zheng SL, Isaacs WB, Xu J. 2008. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 10:897-907.
32. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
33. Nilsson T, Nilsson L, Lenhoff S, Rylander L, Strand-Grundstrom I, Strombeck B, Hoglund M, Turesson I, Westin J, Mitelman F, Jacobsen SE, Johansson B. 2004. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer 41:223-231. (Pubitemid 39299292)
34. Noel P, Kyle RA. 1987. Plasma cell leukemia: An evaluation of response to therapy. Am J Med 83:1062-1068. (Pubitemid 18098878)
35. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M. 1994. Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood 84:2597-2603. (Pubitemid 24317392)
36. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:45.
37. Ross FM, Ibrahim AH, Vilain-Holmes A, Winfield MO, Chiecchio L, Protheroe RK, Strike P, Gunasekera JL, Jones A, Harrison CJ, Morgan GJ, Cross NC. 2005. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19:1634-1642. (Pubitemid 43090409)
38. Ruiz-Arguelles GJ, San Miguel JF. 1994. Cell surface markers in multiple myeloma. Mayo Clin Proc 69:684-690. (Pubitemid 24204243)
39. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C, Glass J, Munker R. 2005. Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 78:288-294. (Pubitemid 40471121)
40. Smadja NV, Leroux D, Soulier J, Dumont S, Arnould C, Taviaux S, Taillemite JL, Bastard C. 2003. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 38:234-239. (Pubitemid 37259640)
41. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Hara E, Vousden KH, Peters G. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001-5014. (Pubitemid 28408466)
42. Tasaka T, Berenson J, Vescio R, Hirama T, Miller CW, Nagai M, Takahara J, Koeffler HP. 1997. Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. Br J Haematol 96:98-102. (Pubitemid 27047537)
43. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. 2008. Genetic aberrations and survival in plasma cell leukemia. Leukemia 22:1044-1052.
44. Van CB, Durie BG, Spier C, De WM, Van Riet I, Vela E, Frutiger Y, Richter L, Grogan TM. 1990. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 76:377-382.
45. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC, Ross FM, Davies FE, Morgan GJ. 2006. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 108:1733-1743. (Pubitemid 44316144)
46. Weh HJ, Gutensohn K, Selbach J, Kruse R, Wacker-Backhaus G, Seeger D, Fiedler W, Fett W, Hossfeld DK. 1993. Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer 29:1269-1273. (Pubitemid 23169895)
47. Wuilleme S, Robillard N, Lode L, Magrangeas F, Beris H, Harousseau JL, Proffitt J, Minvielle S, vet-Loiseau H. 2005. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19:275-278.
48. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD, Jr. 2006. The molecular classification of multiple myeloma. Blood 108:2020-2028.